<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384966</url>
  </required_header>
  <id_info>
    <org_study_id>ID-076A201</org_study_id>
    <nct_id>NCT03384966</nct_id>
  </id_info>
  <brief_title>A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find out if a drug called ACT-246475 can prevent platelets from
      binding together when administered by an injection under the skin in the thigh or in the
      belly. Another goal is to know how fast and for how long ACT-246475 works and if there is a
      difference if the drug is injected in the thigh or in the belly. This study will also help to
      find out more about the safety of this new drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Actual">September 18, 2018</completion_date>
  <primary_completion_date type="Actual">August 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinding will apply to treatment (ACT-246475 vs placebo). The dose (8 mg vs 16 mg) will be single blinded (subject blinded). The site for the sub-cutaneous injection (thigh vs abdomen) will not be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>From 15 min after beginning of injection of to 24 hours</time_frame>
    <description>The primary outcome measure is the pharmacodynamic response that is defined for each subject as a P2Y12 Reaction Units &lt; 100 starting 30 min after injection and lasting for at least 3 h, as measured via the VerifyNow® assay. This corresponds to inhibition of ADP-induced platelet aggregation (IPA) &gt; 80%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration - Cmax</measure>
    <time_frame>From 15 min after beginning of injection of to 24 hours</time_frame>
    <description>Cmax will be derived by noncompartmental analysis of the plasma concentration-time profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration - tmax</measure>
    <time_frame>From 15 min after beginning of injection of to 24 hours</time_frame>
    <description>Tmax will be derived by noncompartmental analysis of the plasma concentration-time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 24 h time point - AUC0-24</measure>
    <time_frame>From 15 min after beginning of injection of to 24 hours</time_frame>
    <description>AUC0-24h will be derived by noncompartmental analysis of the plasma concentration-time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">346</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Selatogrel 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-246475 is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selatogrel 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-246475 is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-246475</intervention_name>
    <description>ACT-246475 is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials contain 22 mg of lyophilized ACT-246475A (hydrochloride salt of ACT-246475) for reconstitution with water for injection.</description>
    <arm_group_label>Selatogrel 16 mg</arm_group_label>
    <arm_group_label>Selatogrel 8 mg</arm_group_label>
    <other_name>Selatogrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for subcutaneous administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  1. Signed informed consent prior to any study-mandated procedure.

          -  2. Male and female subjects aged from 18-85 years, inclusive.

          -  3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and
             at Visit 2 before randomization.

          -  4. Stable CAD defined by the presence of any of the following conditions:

               1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.

               2. Previously documented myocardial infarction occurring more than 3 months prior to
                  randomization.

          -  5. Antiplatelet background therapy stable for at least 1 month prior to randomization.

          -  6. Body weight ≥ 40.0 kg (88.2 lbs).

        Main Exclusion Criteria:

          -  1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for
             peripheral artery disease within 3 months prior to randomization.

          -  2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to
             randomization.

          -  3. Active internal bleeding, or medical history of recent (&lt; 1 month) bleeding
             disorders or conditions associated with high risk of bleeding (e.g., clotting
             disturbances, gastrointestinal bleed, hemoptysis).

          -  4. Hemoglobin ≤ 10 g/dL at screening.

          -  5. Loss of at least 250 mL of blood within 3 months of screening.

          -  6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior
             to screening (Visit 1).

          -  7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand
             disease).

          -  8. Pregnant or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida (UF) Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Tampa - Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine - Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Cardiology</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOUNT SINAI HOSPITAL (New York)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Center For Thrombosis Research and Translational Medic</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>40530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital - Cardiothoracic Dept</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East &amp; North Hertfordshire NHS Trust - Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <zip>SG14AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <disposition_first_submitted>July 11, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 17, 2019</disposition_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

